• About Us
  • Overview
  • Strategy
  • Management >
    • Board of Directors
    • Senior Management
  • Scientific Advisory Board
  • Job Opportunities
• Clinical Trials
  • Overview
• Products
  • Advanced Pipeline >
    • TroVax^®
    • ProSavin^®
    • Hi-8 MEL^®
    • MetXia^®
    • RetinoStat^®
  • Early-stage Pipeline >
    • StarGen^®
    • MoNuDin^®
    • SMN-1G
    • Innurex^®
    • ReQuinate^®
    • ImmStat^®
    • EndoAngio-GT
    • Targeted Antibody
• Technology
  • Gene Delivery Technologies
  • Gene Discovery and Target Validation
  • Antibody Delivery
  • Hypoxia Response Element
• Collaborations
  • Corporate Partnerships
  • Technology Licence Agreements
  • Scientific Collaborations and Advisors
• Investors
  • Financing History
  • Accounts
  • Share Price
  • Presentation >
    • Interim Results August 2008
    • Annual General Meeting May 2008
    • Annual Results March 2007
  • Web Casts
  • Announcements
  • Shareholder Meetings
  • Contact
• News
  • Announcements
  • Events
  • Media Coverage
• Contact Us
  • UK >
    • Contacts
    • Directions
    • Map
  • USA >
    • Contacts
    • Directions
    • Map

Alex Lewis, PhD Non-Executive Director Alex Lewis was appointed to Oxford BioMedica’s board in March 2008. Dr Lewis is an experienced consultant to the pharmaceutical and biotech industry with a background in medical research and drug development (23 years). Dr Lewis has been a Consultant with Wood Mackenzie for over nine years and is head of the company’s Partnering and Due Diligence Practice. Dr Lewis has also been involved in the provision of the Expert Reports and technical advice for the Initial Public Offerings (IPOs) and fundraising activities for biotech companies based in the US and Europe.

Back

Website by College Hill - Life Sciences